Improving Aggregate Removal To Enhance Clinical Manufacturing of mAbs
Over the past two decades, monoclonal antibodies (mAbs) have been one of the most dominant segments of the biotherapeutics market. Ensuring mAbs’ safety and efficacy is vital but is made complicated by the fact that antibodies can have a tendency to aggregate during production, decreasing efficacy and increasing the risk of immunogenicity.
Download this whitepaper to discover a hydrophobic interaction chromatography flow-through method that:
- Improves both processes efficiency and productivity
- Allows for process simplification and increased throughput
- Provides an alternate purification option for mAb development
